Is Eloxx Pharmaceuticals, Inc. overvalued or undervalued?

Jun 25 2025 09:17 AM IST
share
Share Via
As of October 1, 2023, Eloxx Pharmaceuticals is fairly valued with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, making it more attractively priced compared to peers like Vertex Pharmaceuticals and Moderna.
As of 1 October 2023, Eloxx Pharmaceuticals, Inc. moved from overvalued to fairly valued. The company currently exhibits a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.5. Compared to its peers, Vertex Pharmaceuticals has a price-to-earnings ratio of 20.5, while Moderna shows a price-to-book ratio of 3.1, indicating that Eloxx is more attractively priced relative to these industry leaders.

Overall, Eloxx appears fairly valued given its current financial metrics and competitive positioning within the biotechnology sector. Recent stock performance has been relatively stable compared to the Sensex, reinforcing the notion that it is appropriately priced in the current market environment.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News